Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ocular inflammation is a broad clinical term encompassing various inflammatory conditions of the eye, including uveitis, scleritis, and keratitis (StatPearls, NBK532252). It is characterized by an immune response involving the infiltration of leukocytes and the production of pro-inflammatory cytokines such as TNF-alpha and various interleukins (PubMed, PMID: 30630136). This condition is not a single molecular target but a complex pathological state that can lead to significant morbidity, including permanent vision loss if not managed effectively (Mayo Clinic, 2023). Drugs used in this context, such as corticosteroids or biologics, act on specific molecular targets like the glucocorticoid receptor or specific cytokines rather than the condition itself (NIH/NEI, 2023). Therefore, ocular inflammation is considered a therapeutic indication or disease role rather than a discrete protein or receptor target.
Not applicable as this is a disease state or clinical condition rather than a specific molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular inflammation.